Business
Bioventus sells medical-device products for pain treatments, surgical solutions, and restorative therapies across U.S. and international markets.
Bioventus turned profitable in FY2025, nearly doubled FCF, and reduced debt, though revenue was flat and Altman-Z stayed in distress.
The read at a glance✓ Audited against SEC data
- Business mix — Musculoskeletal medical devicesNote
- Revenue — $568.1M, -0.9%Note
- Net income — $22.7M vs lossOK
- FCF — $72.1M, +90.8%OK
- Debt — $279.0M, -9.5%OK
- Insiders — 0 purchases / 3 salesWatch
- Accounting — Altman distress; Beneish clean; EQ safeNote
Where the revenue comes from
Fiscal 2025, as Bioventus Inc. reports it. History and quarterly detail are in the app.
- U.S.$502.1M
- International$66.0M
Leadership changes
From Bioventus Inc.'s own filings, the day they're filed.
- Ajay Dhankhar · director · appointmenteff. 2025-11-14
- Robert E. Claypoole · President · appointmenteff. 2024-01-10
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-21
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Bioventus Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.